Alumis Inc. (ALMS)
Nasdaq: ALMS · Pharmaceutical Preparations · South San Francisco, CA · filing with the SEC since 2021
Who owns Alumis Inc.
As filed with the SECHolders of 5% or more
6
James B. Tananbaum holds 12.7% of Common Stock, as its SCHEDULE 13D/A filed Apr 3, 2026 says.
Directors and officers
13
report now, of 18 people on the record since 2024. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 6 named at left.
Holders of 5% or moreshare of the class, as filed
James B. Tananbaum
SCHEDULE 13D/A · filed Apr 3, 2026 · Common Stock · 14.1% in Jan 12, 2026
AyurMaya Capital Management Company, LP
SCHEDULE 13D/A · filed Jul 2, 2026 · Common Stock, par value $0.0001 per share · 15.8% in May 23, 2025
Deep Track Capital, LP
SCHEDULE 13G · filed Apr 7, 2026 · Common Stock, $0.0001 par value per share
Blackrock, Inc.
SCHEDULE 13G · filed Jul 27, 2026 · Common Stock
Fmr LLC
SCHEDULE 13G · filed Aug 6, 2026 · COMMON STOCK
Srinivas Akkaraju
SCHEDULE 13D/A · filed Jan 13, 2026 · Common Stock, $0.0001 par value per share · 5.3% in Nov 24, 2025
venBio Global Strategic Fund IV, L.P.
SCHEDULE 13G/A · filed Nov 17, 2025 · Common Stock, $0.0001 par value per share · reported falling below 5%
What ALMS reports owning in othersstakes of 5% or more, and other ties
Other ties the annual report names
Acelyrin Inc
A company bought · acquisition · owns, named in the 10-K filed Mar 19, 2026
2 subsidiaries in 1 country, from the list filed with the 10-K filed Mar 19, 2026.
Insider tradesForm 4
15sales
26purchases
0sales on a scheduled plan
7people selling
$1.6Msold, in dollars
$40.4Mbought, in dollars
Open-market trades on Form 4 from Nov 4, 2025 to Nov 4, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2026 runs to Nov 4, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window12 of 29 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| Akkaraju Srinivas | director | 2 | $1.0M | 0 | 19 | $29.8M |
| Pangali Sanam | Chief Legal Officer | 3 | $200,000 | 0 | 0 | $0 |
| Schroer John R. | Chief Financial Officer | 2 | $100,000 | 0 | 0 | $0 |
| Bradley Mark Christopher | Chief Development Officer | 2 | $100,000 | 0 | 0 | $0 |
| Drappa Jorn | Chief Medical Officer | 2 | $100,000 | 0 | 0 | $0 |
| Goldstein David M | Chief Scientific Officer | 2 | $100,000 | 0 | 0 | $0 |
| Hardiman Roy C. | Chief Business & Strategy Ofcr | 2 | $100,000 | 0 | 0 | $0 |
| Tananbaum James B. | director | 0 | $0 | 0 | 7 | $10.6M |
| Foresite Labs Affiliates 2021, LLC | 10% owner | 0 | $0 | 0 | 5 | $3.6M |
| Foresite Capital Management Vi LLC | 10% owner | 0 | $0 | 0 | 4 | $3.1M |
| Foresite Labs Fund I, L.P. | 10% owner | 0 | $0 | 0 | 3 | $7.5M |
| Foresite Labs, LLC | 10% owner | 0 | $0 | 0 | 2 | $7.0M |